Predictors of Pharyngeal Dysphagia in Patients with Parkinson's Disease.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2020
Historique:
pubmed: 11 8 2020
medline: 18 9 2021
entrez: 11 8 2020
Statut: ppublish

Résumé

Diagnosis of pharyngeal dysphagia in patients with Parkinson's disease is often difficult as reliable screening methods are lacking so far and clinical examination fails to adequately assess the pharyngeal phase of swallowing. To identify clinical predictors indicating the presence of pharyngeal dysphagia in patients at risk. We examined pharyngeal dysphagia in a large cohort of patients with Parkinson's disease (n = 200) divided in three clinical subtypes (tremor-dominant (TD), mainly bradykinetic (BK) and early postural instability and gait difficulty PIGD)) by using flexible endoscopic evaluation of swallowing. ANOVA-multivariance analysis and following t-tests as well as binary logistic regression analysis were performed to detect group differences and to identify clinical predictors for dysphagia. Statistically significant differences were found in the dysphagic group: age, male gender, disease duration, stage of the disease, Levodopa equivalent dose and higher scores on the Unified Parkinson's disease rating scale III and II, item 7. The PIGD subtype was affected more frequently than the TD and BK subtype. In a logistic regression model higher age (>63.5 years p < 0.05) and Levodopa equivalent dose (>475 mg, p < 0.01) were identified to be independent predictors for the presence of pharyngeal dysphagia. Particularly patients with an age > 63.5 years and a daily Levodopa equivalent dose >475 mg show an increased risk for pharyngeal dysphagia. These findings may partly be influenced by presbyphagia but are likely to represent disease progression. The PIGD subtype seems to be a risk factor due to more pronounced dyscoordination of oropharyngeal muscle movements.

Sections du résumé

BACKGROUND
Diagnosis of pharyngeal dysphagia in patients with Parkinson's disease is often difficult as reliable screening methods are lacking so far and clinical examination fails to adequately assess the pharyngeal phase of swallowing.
OBJECTIVE
To identify clinical predictors indicating the presence of pharyngeal dysphagia in patients at risk.
METHODS
We examined pharyngeal dysphagia in a large cohort of patients with Parkinson's disease (n = 200) divided in three clinical subtypes (tremor-dominant (TD), mainly bradykinetic (BK) and early postural instability and gait difficulty PIGD)) by using flexible endoscopic evaluation of swallowing. ANOVA-multivariance analysis and following t-tests as well as binary logistic regression analysis were performed to detect group differences and to identify clinical predictors for dysphagia.
RESULTS
Statistically significant differences were found in the dysphagic group: age, male gender, disease duration, stage of the disease, Levodopa equivalent dose and higher scores on the Unified Parkinson's disease rating scale III and II, item 7. The PIGD subtype was affected more frequently than the TD and BK subtype. In a logistic regression model higher age (>63.5 years p < 0.05) and Levodopa equivalent dose (>475 mg, p < 0.01) were identified to be independent predictors for the presence of pharyngeal dysphagia.
CONCLUSION
Particularly patients with an age > 63.5 years and a daily Levodopa equivalent dose >475 mg show an increased risk for pharyngeal dysphagia. These findings may partly be influenced by presbyphagia but are likely to represent disease progression. The PIGD subtype seems to be a risk factor due to more pronounced dyscoordination of oropharyngeal muscle movements.

Identifiants

pubmed: 32773397
pii: JPD202081
doi: 10.3233/JPD-202081
doi:

Substances chimiques

Antiparkinson Agents 0
Levodopa 46627O600J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1727-1735

Auteurs

Inga Claus (I)

Department of Neurology with Institute of Translational Neurology, University Hospital of Muenster, Muenster, Germany.

Paul Muhle (P)

Department of Neurology with Institute of Translational Neurology, University Hospital of Muenster, Muenster, Germany.

Judith Suttrup (J)

Department of Neurology with Institute of Translational Neurology, University Hospital of Muenster, Muenster, Germany.

Bendix Labeit (B)

Department of Neurology with Institute of Translational Neurology, University Hospital of Muenster, Muenster, Germany.

Sonja Suntrup-Krueger (S)

Department of Neurology with Institute of Translational Neurology, University Hospital of Muenster, Muenster, Germany.

Rainer Dziewas (R)

Department of Neurology with Institute of Translational Neurology, University Hospital of Muenster, Muenster, Germany.

Tobias Warnecke (T)

Department of Neurology with Institute of Translational Neurology, University Hospital of Muenster, Muenster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH